LX201 is a silicone matrix ocular implant that provides sustained release of cyclosporine A (CsA) locally to the eye over the course of one year. LX201 is implanted subconjunctivally (beneath... LX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) in a minimally invasive procedure.
- Mechanism
- Curator reviewed
LX201 provides a delivery mechanism for cyclosporine. Cyclosporine binds to cyclophillin. The complex then inhibits calcineurin which is normally responsible for activating transcription of interleukin 2. Cyclosporine also inhibits lymphokine production and interleukin release.
- Primary indication
- Investigated for use/treatment in eye disorders/infections and transplant (rejection).Curator reviewed
- Code names
- LX201
Resolves to
What you can answer from here — as of October 01, 2026
Which companies are running trials of LX201, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account